Scancell Holdings Plc (‘Scancell’ LSE:AIM SCLP), the developer of novel immunotherapies for the treatment of cancer, announces the grant of a share option to Dr John Chiplin. Further to the announcement of his
appointment as non-executive Chairman of the Company in January 2016, Dr John Chiplin has been granted an option over 3,000,000 ordinary shares, under a one-off option grant.
The option vests over a period of three years in three equal tranches, subject to the achievement of performance criteria as specified by the Remuneration Committee. The exercise price payable in respect of the option is 17p per share; being the price paid by shareholders in the recent Placing and Open Offer.
For Further Information:
|Dr Richard Goodfellow, Joint CEO
||Scancell Holdings Plc
||+ 44 (0) 20 3727 1000
|Professor Lindy Durrant, Joint CEO
|Robert Naylor (Corporate Finance)
||Panmure Gordon & Co
||+44 (0) 20 7886 2714
|Maisie Atkinson (Sales)
||+44 (0) 20 7886 2905
|Mo Noonan/Simon Conway
||+ 44 (0) 20 3727 1000
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial.
Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.